Oragenics, Inc. Changes Name to ONI Biopharma Inc.
13 Mayo 2008 - 8:00AM
Marketwired
ALACHUA, FL announced today that its Board of Directors approved
the use of the Company's new name of ONI BioPharma Inc. The Company
recently registered in the State of Florida to do business as "ONI
BioPharma Inc." The Company will refer to itself as ONI BioPharma
from this point forward and expects to seek to obtain shareholder
approval to amend its articles of incorporation in order to
formally change its name from Oragenics, Inc. to ONI BioPharma Inc.
in connection with the next annual meeting of shareholders. The
Company believes that the new name more accurately reflects the
broad range of scientific platforms and products that the Company
has under development through the efforts of its scientific team,
headed by Dr. Jeffrey Hillman, our Chief Scientific Officer.
Our Chairman, Richard T. Welch, stated that, "Although we remain
committed to oral health, the Company is active in the development
of novel antibiotics and diagnostics as well and the new 'doing
business name,' ONI BioPharma, conveys a better sense of a company
that is active in other areas, in particular the infectious
diseases arena."
Notwithstanding our doing business as ONI BioPharma Inc, and our
expected future formal name change, our common stock will continue
to trade under the stock symbol "ONI" on the American Stock
Exchange.
About Oragenics
Oragenics, Inc. (d/b/a ONI BioPharma Inc.) is a
biopharmaceutical company with a pipeline of proprietary
technologies. The Company has a number of products in discovery,
preclinical and clinical development, with a concentration in the
main therapeutic area of infectious diseases. Our core pipeline
includes products and supporting platform technologies for use in
the treatment and diagnosis of bacterial infections.
Safe Harbor Statement: Under the Private Securities Litigation
Reform Act of 1995: This release includes forward-looking
statements that reflect Oragenics Inc.'s (d/b/a ONI BioPharma)
current views with respect to future events and financial
performance. These forward-looking statements are based on
management's beliefs and assumptions and information currently
available. The words "believe," "expect," "anticipate," "intend,"
"estimate," "project" and similar expressions that do not relate
solely to historical matters identify forward-looking statements.
Investors should be cautious in relying on forward-looking
statements because they are subject to a variety of risks,
uncertainties, and other factors that could cause actual results to
differ materially from those expressed in any such forward-looking
statements. These factors include, but are not limited to those set
forth in our most recently filed annual report on Form 10-KSB and
quarterly report on Form 10-Q, and other factors detailed from time
to time in filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update forward-looking
statements.
Contact: Oragenics, Inc. Stanley B. Stein 386-418-4018 X222
www.oragenics.com
Oragenics (AMEX:ONI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Oragenics (AMEX:ONI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Oragenics, (American Stock Exchange): 0 recent articles
Más de Oragenics.com Artículos de Noticias